Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Fig. 1

SoLAT (Sorafenib Lenvatinib Alternating Treatment) suppressed proliferation of GSP2 (patient-derived papillary thyroid carcinoma cells). a Information on the secondary established PTC cell line GSP2 and GSP3. b MTT assay for analysis of cell proliferation presence of sorafenib and lenvatinib. c Estimation of IC50 of the PTC cell line treated with sorafenib and lenvatinib

Back to article page